You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,923,968


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,923,968
Title: Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis
Abstract:The present invention relates to a novel method for treating a patient that has osteoporosis and the patient may be having administered cyclase activating parathyroid hormone (CAP) or analogues. The patient receives an administration of a cyclase inhibiting parathyroid hormone peptide (CIP) having an amino acid sequence from between (SEQ ID NO:1 [PTH.sub.2-84 ]) and (SEQ ID NO:3 [PTH.sub.34-84 ]) (i.e., a contiguous portion of PTH having an amino acid sequence set forth in SEQ ID NO:5 (PTH.sub.1-84), having the N-terminal amino acid residue starting at any position spanning from position 2 through position 34 of the PTH.sub.1-84, and the C-terminal amino acid residue ending at position 84 of the PTH.sub.1-84), (preferably (SEQ ID NO:2 [PTH.sub.3-84 ]) and (SEQ ID NO:8 [PTH.sub.28-84 ])), or a conservatively substituted variant thereof exhibiting parathyroid hormone (PTH) antagonist activity in a therapeutically effective, but non-toxic amount that reduces the occurrence of hypercalcemia or osteosarcoma in the patient resulting from the administration of CAP, and yet, through a CAP rebound effect, is effective in itself in the treatment of osteoporosis.
Inventor(s): Cantor; Thomas L. (El Cajon, CA)
Assignee: Scantibodies Laboratory, Inc. (Santee, CA)
Application Number:09/928,047
Patent Claims:1. A method for reducing the occurrence of hypercalcemia or osteosarcoma in a patient, wherein said patient has osteoporosis and has received administration of, or is being administered, cyclase activating parathyroid hormone (CAP) or analogues thereof, said method comprising also administering a cyclase inhibiting parathyroid hormone peptide (CIP) to said patient in a therapeutically effective, but non-toxic amount, where said CIP comprises a contiguous portion of PTH having amino acid sequence set forth in SEQ ID NO:5 (PTH.sub.1-84), said portion having an N-terminal amino acid residue starting at any position spanning from position 2 through position 34 of the PTH.sub.1-84, and a C-terminal amino acid residue ending at position 84 of the PTH.sub.1-84, or a conservatively substituted variant thereof exhibiting parathyroid hormone (PTH) antagonist activity.

2. The method of claim 1 wherein the CIP has an N-terminal amino acid residue starting at any position spanning from position 3 through position 28 of the PTH.sub.1-84, and a C-terminal amino acid residue ending at position 84 of the PTH.sub.1-84.

3. The method of claim 1, wherein the CIP administered is PTH.sub.7-84.

4. The method of claim 1 wherein the CIP administration is performed in a pulsatile manner.

5. The method of claim 1, wherein the CIP is administered to reduce hypercalcemia.

6. The method of claim 1, wherein the CIP is administered to reduce osteosarcomas.

7. A method for reducing the occurrence of hypercalcemia or osteosarcoma in a patient, wherein said patient has osteoporosis and has received administration of, or is being administered, cyclase activating parathyroid hormone (CAP) or analogues thereof, said method comprising also administering a cyclase inhibiting parathyroid hormone peptide (CIP) to said patient in a therapeutically effective, but non-toxic amount, where said CIP comprises a contiguous portion of PTH having an amino acid sequence set forth in SEQ ID NO:5 (PTH.sub.1-84), said portion having an N-terminal amino acid residue starting at any position spanning from position 2 through position 34 of the PTH.sub.1-84, and a C-terminal amino acid residue ending at position 84 of the PTH.sub.1-84.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.